Conference
Phase 1 study with expansion cohorts of cabozantinib (C) + abiraterone (A) in metastatic castration resistant prostate cancer (mCRPC): Investigator-sponsored study.
Authors
Sweeney C; Gray KP; Harshman LC; Taplin M-E; Pace AF; Dumas K; Supko JG; Zukotynski KA; Bernard BD; Pomerantz M
Volume
33
Pagination
pp. 5037-5037
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2015
DOI
10.1200/jco.2015.33.15_suppl.5037
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X